Comunicati Stampa
Ambiente

Piramal Pharma unveils its Sustainability Report FY21-22, articulating its ESG journey to accelerate the pace of integrating sustainability practices

To view the Company's ESG strategy, framework and targets, please download the full report: PPL Sustainability Report FY21-22  To view the Company's ESG strategy, framework and targets, please download the full report: PPL Sustainability Report FY21-22  Nandini Piramal, Executive Director of Piramal Enterprises and Chairperson of Piramal Pharma Limited,says, " Piramal has always prioritised sustainability practices at its core across all its operations. We have been taking significant...
MUMBAI, India, (informazione.news - comunicati stampa - ambiente)

To view the Company's ESG strategy, framework and targets, please download the full report:  

says, " "

says,   

The Report demonstrates PPL's intent of sharing its sustainability performance and targets with its stakeholders. Towards this, the Company also responded to the CDP Climate Change and Water Security disclosures. Further, the Company is committed to achieving value chain-based sustainability by engaging with its customers and suppliers on various business aspects, including those related to ESG. PPL is also a member of the Pharmaceutical Supply Chain Initiative (PSCI).

During FY21–22, the Company developed an ESG framework. The framework has 12 focus areas, guiding PPL's strategic and operational imperatives. This year, PPL undertook specific objective targets and timelines to achieve its ESG goals as the next steps in its ESG journey.

Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organisation; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020 , PPL received 20% strategic growth investment from the Carlyle Group.

For more information visit: https://www.piramal.com/piramal-pharma/, Facebook, Twitter, LinkedIn

Photo - https://mma.prnewswire.com/media/1920356/ESG_Framework.jpg
Logo - https://mma.prnewswire.com/media/1855206/Piramal_Pharma_Limited_Logo.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/piramal-pharma-unveils-its-sustainability-report-fy2122-articulating-its-esg-journey-to-accelerate-the-pace-of-integrating-sustainability-practices-301648281.html

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Non disponibili